Tag: Swedish biotech company
AKIR001 study selected as overall featured article
The preclinical study underpinning the clinical development of Akiram Therapeutics’ lead candidate AKIR001, published in The Journal of Nuclear Medicine (JNM), has been selected...
Akiram Therapeutics research selected as Top Rated Oral Presentations at EANM...
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will contribute to several academic presentations at the EANM Congress 2025 in Barcelona, October...
Akiram’s Phase I clinical trial with AKIR001 progresses to next step
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, has announced the completion of the first cohort in the clinical Phase I trial...
Clinical trial of Akiram’s cancer drug candidate AKIR001
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announced that the first patient has been enrolled in the Phase 1 clinical trial...